<DOC>
	<DOCNO>NCT00134095</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , S-1 irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Giving chemotherapy surgery may shrink tumor completely remove . PURPOSE : This phase II trial study well give S-1 together irinotecan work treat patient undergo surgery locally advance stomach cancer .</brief_summary>
	<brief_title>S-1 Irinotecan Treating Patients Who Are Undergoing Surgery Locally Advanced Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy neoadjuvant S-1 irinotecan patient locally advanced gastric cancer . Secondary - Determine histological response patient treat regimen . - Determine overall survival patient treat regimen . - Determine progression-free survival patient treat regimen . - Determine toxicity regimen patient . - Determine postoperative morbidity patient treat regimen . - Determine rate potentially curative surgery patient treat regimen . OUTLINE : This multicenter study . Patients receive oral S-1 day 1-21 irinotecan IV 90 minute day 1 15 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . Patients undergo gastrectomy lymphadenectomy . After surgery , patient resume treatment S-1 alone 1 year . PROJECTED ACCRUAL : A total 70 patient accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm gastric adenocarcinoma Locally advance disease Clinical stage T34 , N03 , M0 ( accord Japanese gastric cancer classification ) Planning undergo curative surgery neoadjuvant chemotherapy PATIENT CHARACTERISTICS : Age 20 75 Performance status ECOG 01 Life expectancy Not specify Hematopoietic WBC 4,00012,000/mm^3 Granulocyte count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Hepatic AST ALT ≤ 100 U/L Bilirubin ≤ 1.5 mg/dL Renal Creatinine normal OR Creatinine clearance ≥ 50 mL/min Pulmonary PaO_2 &gt; 60 mm Hg room air Other Able swallow oral medication PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy gastric cancer Chemotherapy No prior chemotherapy gastric cancer Endocrine therapy No prior endocrine therapy gastric cancer Radiotherapy No prior radiotherapy gastric cancer Surgery No prior surgery gastric cancer Other No prior therapy gastric cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
</DOC>